Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
ID: 345392Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345392

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-102.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)" aimed at advancing research on mood and psychotic disorders during the menopause transition. This initiative seeks innovative projects that explore the neurobiological and behavioral mechanisms underlying these mental health issues, with a focus on identifying potential preventative approaches and interventions. The research is particularly relevant for understanding mood disruptions and psychosis in a vulnerable population, emphasizing the need for rigorous methodologies and interdisciplinary collaboration. Eligible applicants include a wide range of institutions, and the maximum budget for projects is capped at $275,000 over two years. Interested parties should note that the application deadline is January 7, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-102.html
    The Department of Health and Human Services, in conjunction with the National Institutes of Health (NIH), has announced a funding opportunity aimed at advancing research on mood disruption and psychosis during the menopausal transition, designated as R21 (Clinical Trial Optional). This initiative seeks projects that explore the neurobiological and behavioral mechanisms behind these mental health issues, particularly focusing on identifying potential preventative approaches and interventions. The research is urged to adopt a dimensional perspective, enhancing understanding by considering participants across varying degrees of severity rather than strictly adhering to existing diagnostic frameworks. The funding announcement allows for applications from diverse research teams and encourages those with innovative, high-risk projects, particularly those lacking preliminary data. Eligible applicants are diverse institutions, including higher education, nonprofits, and government entities. The maximum two-year budget is capped at $275,000. This FOA emphasizes the importance of rigorous methodological standards and collaborative research aimed at addressing an unmet medical need within a vulnerable population.
    Similar Opportunities
    Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)" aimed at advancing research on mood and psychotic disorders during the menopause transition. This grant seeks to support innovative and high-risk projects that explore the neurobiological and behavioral mechanisms underlying mood disruptions and psychosis, with the goal of identifying targets for future treatment interventions. The initiative emphasizes the importance of interdisciplinary collaboration among researchers in neuroscience, psychiatry, and related fields, while adhering to rigorous scientific standards to address health disparities among women experiencing menopause. Interested applicants can find more information and application guidelines at the provided link, with a submission deadline of January 7, 2025, and no cost-sharing or matching requirements.
    Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)" aimed at advancing research on mood and psychotic disorders in women during the menopausal transition. This initiative seeks to explore the neurobiological and behavioral mechanisms underlying these disorders, with the goal of identifying new targets for mental health interventions and encouraging interdisciplinary collaboration among researchers. The funding opportunity is particularly significant as it addresses critical gaps in understanding and treating mental health challenges faced by women during menopause, an urgent area in women's health research. Interested applicants can submit proposals starting from January 5, 2025, with a project period of up to five years, and should refer to the full announcement for detailed application guidelines and requirements. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life" (PAR-24-026), aimed at advancing research on the onset and progression of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to promote high-risk exploratory and developmental projects that investigate neurobiological, psychosocial, and environmental factors contributing to these disorders, with a particular emphasis on addressing health disparities among minority and aging populations. The program offers a maximum funding amount of $275,000 over two years, with applications due by November 16, 2023, for the initial cycle. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Schizophrenia and related disorders during mid- to late-life (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory research on schizophrenia and related disorders in individuals aged 35 and older, through the R21 grant mechanism. This initiative aims to enhance understanding of the onset, trajectory, and outcomes of these disorders in mid- to late-life, encouraging innovative studies that identify biological, behavioral, and environmental risk factors, as well as potential interventions. The funding, which can reach up to $275,000 over a maximum of two years, is crucial for addressing health disparities faced by older adults with these disorders and promoting novel solutions for their care. Applications are due between January 2025 and October 2026, and interested parties can contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia," aimed at enhancing the understanding of neuropsychiatric symptoms associated with Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). This initiative invites exploratory research to identify the neurobiological and behavioral pathways that contribute to symptoms such as aggression, depression, anxiety, and agitation, with the goal of discovering novel therapeutic approaches for treatment. The funding, available through the R21 grant mechanism, supports diverse methodologies and interdisciplinary collaboration, with a maximum budget of $275,000 over two years. Applications are due by September 7, 2026, and eligible applicants include a wide range of institutions and organizations, including educational institutions, non-profits, and foreign entities. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 exploratory research grant focused on understanding neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) and related dementias (ADRD). This funding opportunity aims to enhance knowledge of the neurobiological and behavioral mechanisms underlying symptoms such as aggression, anxiety, and agitation, which significantly impact patient care and outcomes. The initiative is part of a broader national effort to address the complexities of Alzheimer's care, with funding capped at $275,000 over two years, and applications opening on January 16, 2025. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and Related Disorders During Mid- to Late-Life," aimed at advancing research on the emergence and trajectory of schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to identify biological, psychosocial, and environmental mechanisms affecting this population to develop effective prevention and treatment strategies, addressing a critical gap in mental health research. The funding utilizes the R01 grant mechanism, with applications accepted starting January 5, 2025, and a project period of up to five years. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov. The application deadline is September 7, 2026.
    Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)" aimed at encouraging research into high-confidence risk factors associated with complex brain disorders such as schizophrenia, bipolar disorder, and major depression. This initiative supports exploratory developmental research (R21) to identify molecular, cellular, and circuit mechanisms involved in these disorders, utilizing diverse experimental paradigms without the necessity for prior feasibility data. The funding amount is capped at $275,000 over two years, with a maximum of $200,000 per year, and eligible applicants include a wide range of educational institutions, nonprofits, and for-profit organizations. Interested parties can find more information and application details at the NIH website, with the application deadline set for September 7, 2026.
    Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Schizophrenia and related disorders during mid- to late-life (R01 Clinical Trial Optional)" aimed at advancing research on schizophrenia and related disorders in individuals aged 35 and older. This initiative seeks to explore the mechanisms, trajectories, and outcomes of these disorders, with a focus on identifying targets for prevention and treatment interventions, particularly emphasizing the inclusion of diverse research teams and individuals with lived experience. The funding is available through the R01 grant mechanism, with applications due by September 7, 2026, and interested applicants are encouraged to adhere strictly to the application guidelines and contribute data to the National Institute of Mental Health Data Archive. For further information, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-023.html.
    NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Mental Health (NIMH), is offering the Exploratory/Developmental Research Grant (R21), which aims to support high-risk and innovative research projects that align with the mission of advancing mental health research. This grant is specifically designed for the early stages of research that may lead to significant breakthroughs in clinical and biomedical fields related to mental health, with a funding limit of $275,000 over a two-year period. Eligible applicants include a diverse range of organizations such as higher education institutions, non-profits, and tribal governments, emphasizing the importance of innovative approaches in addressing critical barriers in mental health research. Interested parties should note that applications are due by January 7, 2025, and must adhere to NIH guidelines, with further inquiries directed to grantsinfo@nih.gov.